Buspirone/testosterone - Emotional Brain

Drug Profile

Buspirone/testosterone - Emotional Brain

Alternative Names: Buspirone/testosterone; Lybridos

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator Emotional Brain
  • Developer Companion Diagnostics BV; Emotional Brain
  • Class Androstenols; Hormonal replacements; Pyrimidines; Small molecules; Spiro compounds; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Serotonin 1A receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Female sexual dysfunction

Most Recent Events

  • 05 Jan 2016 A phase III trial for Female sexual dysfunction is still being planned in USA and Europe
  • 20 Apr 2015 Emotional Brain plans a phase III trial for Female sexual dysfunction in USA and Europe
  • 20 Apr 2015 Buspirone/testosterone has patent protection in Europe, Japan, China, Australia, Canada, Hong Kong, USA and Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top